#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiac arrest Conjunctivitis allergic Short stature homeobox gene mutation Bronchiectasis Ewing's sarcoma Encephalitis autoimmune Acquired haemophilia Marfan's syndrome Peripheral T-cell lymphoma unspecified Rhabdomyosarcoma recurrent Glomerulonephritis acute Follicular lymphoma stage I Cold type haemolytic anaemia Renal cell carcinoma Breast cancer metastatic More trials…

    Learn about Rare Diseases

    Fabry’s disease – Diagnostics Alagille syndrome – Basic Information Sarcoidosis – Trials in Disease IgA nephropathy – Life with Disease Cytokine release syndrome – Diagnostics Factor VIII deficiency – Basic Information Lymphatic malformation – Treatment Osteosarcoma metastatic – Diagnostics Lennox-Gastaut syndrome – Diagnostics Retinoblastoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LUXDEGALUTAMIDE Dexibuprofen Isis 696844 Vinflunine Pregabalin Ketotifen Hydrogen Fumarate Sodium Citrate TRIACYLGLYCEROL LIPASE Levamlodipine Succinate Jk06 Iopromide Imetelstat Sodium VG801-2 Palmidrol Thiopental Sodium Gt005 M-(18F)-Fluorobenzylguanidine Bictegravir Prasinezumab Tucidinostat More therapies…

    Learn about Your Condition

    Staphylococcal bacteraemia Vulvovaginal pain Prodromal Alzheimer's disease Breast proliferative changes Juvenile absence epilepsy Hepatitis B Pneumonia chlamydial Retinopathy of prematurity Demyelination Pathogen resistance Diabetic nephropathy Pituitary tumour benign Tendon disorder Tumour thrombosis Multiple system atrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Emphysema

  • Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Alpha-1-Proteinase Inhibitor (Human)
    Denmark Estonia Finland France Poland Sweden

  • Study on the Effects of Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1 Antitrypsin Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Emphysema
    Investigated Drugs:
    • Alpha-1-Proteinase Inhibitor (Human)
    Denmark Finland France Poland Sweden

  • Study on Long-Term Safety of INBRX-101 for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Emphysema
    • Alpha-1 antitrypsin deficiency
    Investigated Drugs:
    • Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant
    Denmark Ireland Poland Spain Sweden

  • Study on the Safety of NTLA-3001 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Emphysema
    Investigated Drugs:
    • Messenger Rna Encoding Cas9
    • Serpina1(Human)-Aav8-1
    • Single Guide Rna Containing A Sequence Complementary To Human Alb Locus Gene, Intron 1, Target Region
    Ireland

  • Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant
    • Human Alpha1-Proteinase Inhibitor
    Denmark Ireland Poland Spain Sweden

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!